Safety and efficacy of statin treatment alone and in combination with fibrates in patients with dyslipidemia: A meta-analysis

Current Medical Research and Opinion

Volumn 30, Issue 1, 2014, Pages 1-10

  Choi, Hye Duck ^a   Shin, Wan Gyoon ^b  

^a Dongguk University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Adverse events; Dyslipidemia; Fibrates; Lipid profiles; Statins

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CHOLESTEROL; CIPROFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADVERSE OUTCOME; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA; KIDNEY DISEASE; LIVER DISEASE; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MUSCLE DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FIBRIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; KIDNEY; LIVER; MUSCLES; RISK; TRIGLYCERIDES;

EID: 84890495215     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.842165     Document Type: Article

References (35)

1. Sofat R, Hingorani AD, Smeeth L, et al. Separating the mechanism-based and off-Target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation 2010;121:52-62
2. Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol 2007;49:1753-62
3. McKenney JM, Davidson MH, Jacobson TA, Guyton JR, National Lipid Association Statin Safety Assessment Task F. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006;97:89-94C
4. Wensel TM, Waldrop BA, Wensel B. Pitavastatin: A new HMG-CoA reductase inhibitor. Ann Pharmacother 2010;44:507-14
5. Filippatos T, Milionis HJ. Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opin Investig Drugs 2008;17:1599-614
6. McKenney JM. Introduction. Report of the National Lipid Association's Safety Task Force: The nonstatins. Am J Cardiol 2007;99:1-58C
7. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990;264:71-5
8. Marais GE, Larson KK. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. Ann Int Med 1990;112: 228-30
9. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12
10. Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101-29
11. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of diseases. J Natl Cancer Inst 1959;22:719-48
12. DerSimonian R, Laird N. Meta-Analysis in clinical trials. Control Clin Trials 1986;7:177-88
13. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101
14. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-Analysis detected by a simple, graphical test. BMJ 1997;315:629-34
15. Wiklund O, Angeline B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993;94:13-20
16. Kontopoulos A, Athyros V, Papageorgiou A, et al. Effect of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coron Artery Dis 1996;7:843-50
17. Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002;25:1198-202
18. Derosa G, Cicero AE, Bertone G, et al. Comparison of fluvastatinfenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: A 12-month, randomized, double-blind, controlled trial. Clin Ther 2004;26:1599-607
19. Fegan P, Shore A, Mawson D, et al. Microvascular endothelial function in subjects with type 2 diabetes and the effect of lipid-lowering therapy. Diabet Med 2005;22:1670-6
20. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005;95:462-8
21. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005;45:1649-53
22. Derosa G, Maffioli P, Salvadeo S, et al. Fenofibrate, simvastatin and their combination in the management of dyslipidemia in type 2 diabetic patients. Curr Med Res Opin 2009;25:1973-83
23. Constantinides A, de Vries R, van Leeuwen JJ, et al. Simvastatin but not bezafibrate decreases plasma lipoprotein-Associated phospholipase A2 mass in type 2 diabetes mellitus: Relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity. Euro J Intern Med 2012;23:633-8
24. Napoli C, Lepore S, Chiariello P, et al. Long-Term treatment with pravastatin alone and in combination with gemfibrozil in familial type IIB hyperlipoproteinemia or combined hyperlipidemia. J Cardiovasc Pharmacol Ther 1997;2:17-26
25. Pauciullo P, Borgnino C, Paoletti R, et al. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis 2000;150:429-36
26. Durrington PN, Tuomilehto J, Hamann A, et al. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract 2004;64:137-51
27. Jones PH, Cusi K, Davidson MH, et al. Efficacy and safety of fenofibric acid co-Administered with low-or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: Results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am J Cardiovasc Drugs 2010;10:73-84
28. Mohiuddin SM, Pepine CJ, Kelly MT, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled study. Am Heart J 2009;157: 195-203
29. Roth EM, McKenney JM, Kelly MT, et al. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: A randomized, double-blind study. Am J Cardiovasc Drugs 2010;10:175-86
30. Roth EM, Rosenson RS, Carlson DM, et al. Efficacy and safety of rosuvastatin 5mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia-A phase 3 study. Cardiovasc Drugs Ther 2010;24:421-8
31. Goldberg AC, Bittner V, Pepine CJ. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia. Am J Cardiol 2011;107:898-905
32. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009;5:150-9
33. Enger C, Gately R, Ming EE, et al. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy. Am J Cardiol 2010;106:1594-601
34. Beukhof C, Van De Oever C, Cabezas MC, Schrama Y. Fibrate induced renal insufficiency. Eur J Intern Med 2011;22(Suppl 1):s11-12
35. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibratestatin versus gemfibrozilany statin. Am J Cardiol 2005;95:120-2